CSRC Approves IPO of JD Capital-invested Fushine Pharmaceutical


On June 12, China Securities Regulatory Commission (CSRC) announced that Jiangxi Fushine Pharmaceutical Co., Ltd. (hereinafter referred to as Fushine Pharmaceutical) invested by JD Capital was approved to launch the Initial Public Offering (IPO), and would be listed on the A-share market soon.

Established in 2002, Fushine Pharmaceutical is an innovation-oriented enterprise specializing in the R&D, production, marketing and services related to chemicals. It has three wholly-owned subsidiaries, including Jiangxi Xiangtai Pharmaceutical Co., Ltd. Boasting a “Provincial-level Enterprise Technology Center”, Fushine Pharmaceutical has won several awards including the “National High-Tech Enterprise”, “Excellent Enterprise of Jiangxi Province”, etc.

Fushine Pharmaceutical boasts several national patents for invention and more than ten provincial-level key new products and excellent technological new products. It is the biggest production base for bulk pharmaceutical chemical of β-lactamase inhibitor in the world, and one of the main suppliers of carbapenemes and their midbodies. By virtue of its strengths in production technologies, quality management, EHS management and customer service, Fushine Pharmaceutical enjoys good reputation among customers at home and abroad and have established with then cooperation relationships. Its products are sold to over ten countries and regions. 

JD Capital became a shareholder of Fushine Pharmaceutical in 2012. The year 2015 witnesses six more IPO companies invested by JD Capital been listed on the A-share market and 30 on the National Equities Exchange and Quotations (NEEQ).